Elonva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

corifollitropin alfa

Available from:

N.V. Organon

ATC code:

G03GA09

INN (International Name):

corifollitropin alfa

Therapeutic group:

- Ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema,

Therapeutic area:

Reproductive Techniques, Assisted; Ovulation Induction; Investigative Techniques

Therapeutic indications:

Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).

Product summary:

Revision: 23

Authorization status:

Awtorizzat

Authorization date:

2010-01-25

Patient Information leaflet

                                28
B. FULJETT TA’ TAGĦRIF
29
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
ELONVA 100 MIKROGRAMMA SOLUZZJONI GĦALL-INJEZZJONI
ELONVA 150 MIKROGRAMMA SOLUZZJONI GĦALL-INJEZZJONI
corifollitropin alfa
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK
_-_
_ _
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
_-_
_ _
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
_-_
_ _
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
_-_
_ _
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li mhuwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Elonva u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tuża Elonva
3.
Kif għandek tuża Elonva
4.
Effetti sekondarji possibbli
5.
Kif taħżen Elonva
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU ELONVA U GĦALXIEX JINTUŻA
Elonva fih is-sustanza attiva corifollitropin alfa u jagħmel parti
mill-grupp ta’ mediċini msejħa ormoni
gonadotropiċi. L-ormoni gonadotropiċi għandhom rwol importanti
fil-fertilità u r-riproduzzjoni tal-
bniedem. Wieħed minn dawn l-ormoni gonadotropiċi hu l-Ormon li
Jistimula l-Follikuli (FSH), li hu
meħtieġ fin-nisa għat-tkabbir u l-iżvilupp tal-follikuli (boroż
żgħar tondi fl-ovarji tiegħek li fihom il-
bajd) u f’ subien adolexxenti (14-il sena u akbar) għat-trattament
ta’ pubertà li tittardja minħabba
ipogonadiżmu ipogonadotropiku (HH, hypogonadotropic hypogonadism)
flimkien ma’ mediċina
msejħa Gonadotropina Korjonika tal-bniedem (hCG human Chorionic
Gonadotropin).
Fin-nisa
Elonva jintuża biex isseħħ it-tqala f’nisa li jkunu qed jieħdu
kura kontra l-infertilità, bħal
fertilizzazzjoni
_in vitro_
(IVF). IVF tinvolvi l-ġbir ta’ bajd mill-ovarju,
il-fertiliz
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.ISEM IL-PRODOTT MEDIĊINALI
Elonva 100 mikrogramma soluzzjoni għall-injezzjoni
Elonva 150 mikrogramma soluzzjoni għall-injezzjoni
2.GĦAMLA KWALITATTIVA U KWANTITATTIVA
Elonva 100 mikrogramma soluzzjoni għall-injezzjoni
Kull siringa mimlija għal-lest fiha 100 mikrogramma ta’
corifollitropin alfa* f’0.5 mL ta’ soluzzjoni
għall-injezzjoni.
Elonva 150 mikrogramma soluzzjoni għall-injezzjoni
Kull siringa mimlija għal-lest fiha 150 mikrogramma ta’
corifollitropin alfa* f’0.5 mL ta’ soluzzjoni
għall-injezzjoni.
*corifollitropin alfa hu glikoproteina magħmul fiċ-ċelluli
tal-Ovarji tal-Ħamster Ċiniż (CHO) minn
teknoloġija tat-tfassil tad-DNA.
Eċċipjent(i) b’effett magħruf
Dan il-prodott mediċinali fih anqas minn 1 mmol sodium (23 mg)
f’kull injezzjoni, jiġifieri
essenzjalment ‘ħieles mis-sodium’.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.GĦAMLA FARMAĊEWTIKA
Soluzzjoni għall-injezzjoni (injezzjoni).
Soluzzjoni akweja ċara u bla kulur.
4.TAGĦRIF KLINIKU
4.1INDIKAZZJONIJIET TERAPEWTIĊI
Elonva hu indikat għal Stimulazzjoni Kkontrollata tal-Ovarji (COS)
flimkien ma’ antagonist tal-Ormon
li Jerħi Gonadotropin (GnRH) għall-iżvilupp ta’ follikuli
multipli f’nisa li qed jipparteċipaw fi programm
ta’ Teknoloġija Riproduttiva Assistita (ART).
Elonva huwa indikat għat-trattament ta’ subien adolexxenti (14-il
sena u akbar) b’ipogonadiżmu
ipogonadotropiku, flimkien mal-Gonadotropin Korjoniku tal-bniedem
(hCG, human Chorionic
Gonadotropin).
4.2POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Il-kura b’Elonva għal COS għandha tinbeda taħt is-superviżjoni
ta’ tabib b’esperjenza fil-kura ta’
problemi tal-fertilità.
It-trattament b’Elonva għal ipogonadiżmu ipogonadotropiku għandu
jinbeda u jiġi sorveljat minn tabib
b’esperjenza fit-trattament ta’ ipogonadiżmu ipogonadotropiku.
Pożoloġija
Fil-kura ta’ nisa ta’ età riproduttiva, id-doża ta’ Elonva
hija bbażata fuq il-
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-04-2023
Public Assessment Report Public Assessment Report Bulgarian 05-07-2022
Patient Information leaflet Patient Information leaflet Spanish 05-04-2023
Public Assessment Report Public Assessment Report Spanish 05-07-2022
Patient Information leaflet Patient Information leaflet Czech 05-04-2023
Public Assessment Report Public Assessment Report Czech 05-07-2022
Patient Information leaflet Patient Information leaflet Danish 05-04-2023
Public Assessment Report Public Assessment Report Danish 05-07-2022
Patient Information leaflet Patient Information leaflet German 05-04-2023
Public Assessment Report Public Assessment Report German 05-07-2022
Patient Information leaflet Patient Information leaflet Estonian 05-04-2023
Public Assessment Report Public Assessment Report Estonian 05-07-2022
Patient Information leaflet Patient Information leaflet Greek 05-04-2023
Public Assessment Report Public Assessment Report Greek 05-07-2022
Patient Information leaflet Patient Information leaflet English 05-04-2023
Public Assessment Report Public Assessment Report English 05-07-2022
Patient Information leaflet Patient Information leaflet French 05-04-2023
Public Assessment Report Public Assessment Report French 05-07-2022
Patient Information leaflet Patient Information leaflet Italian 05-04-2023
Public Assessment Report Public Assessment Report Italian 05-07-2022
Patient Information leaflet Patient Information leaflet Latvian 05-04-2023
Public Assessment Report Public Assessment Report Latvian 05-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-04-2023
Public Assessment Report Public Assessment Report Lithuanian 05-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 05-04-2023
Public Assessment Report Public Assessment Report Hungarian 05-07-2022
Patient Information leaflet Patient Information leaflet Dutch 05-04-2023
Public Assessment Report Public Assessment Report Dutch 05-07-2022
Patient Information leaflet Patient Information leaflet Polish 05-04-2023
Public Assessment Report Public Assessment Report Polish 05-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 05-04-2023
Public Assessment Report Public Assessment Report Portuguese 05-07-2022
Patient Information leaflet Patient Information leaflet Romanian 05-04-2023
Public Assessment Report Public Assessment Report Romanian 05-07-2022
Patient Information leaflet Patient Information leaflet Slovak 05-04-2023
Public Assessment Report Public Assessment Report Slovak 05-07-2022
Patient Information leaflet Patient Information leaflet Slovenian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 05-04-2023
Public Assessment Report Public Assessment Report Slovenian 05-07-2022
Patient Information leaflet Patient Information leaflet Finnish 05-04-2023
Public Assessment Report Public Assessment Report Finnish 05-07-2022
Patient Information leaflet Patient Information leaflet Swedish 05-04-2023
Public Assessment Report Public Assessment Report Swedish 05-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 05-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 05-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 05-04-2023
Patient Information leaflet Patient Information leaflet Croatian 05-04-2023
Public Assessment Report Public Assessment Report Croatian 05-07-2022

Search alerts related to this product

View documents history